Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

KYMR vs CRSP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KYMR Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)

KYMR Overall Winner 6-Pillar Tally: KYMR 4 – 1 CRSP (1 Tie) Matrix Metrics: KYMR 5 – 4 CRSP

As of Nov 16, 2026, Kymera Therapeutics, Inc. (KYMR) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). KYMR carries a Unified Composite Score of 47.1/100 (HOLD) at $124.79 (N/M Forward P/E, -396.0% operating margin), whereas CRSP carries 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin).

  • Growth vs. Quality Trade-Off: KYMR earns the overall head-to-head edge with a stronger Unified Composite Score (47.1/100 HOLD vs. CRSP 44.7/100 HOLD) and 1.04β · 54% Vol risk profile, whereas CRSP leads top-line expansion (+1325.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: KYMR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.7); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KYMR vs CRSP
KYMR NASDAQ Head-to-Head Winner
Kymera Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$124.79
-2.18% 1D
Market Cap $10.9B
TTM Revenue $102M
Forward P/E N/M
Beta / 30D Vol 1.04β · 54% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 36.0 Fund 50.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.0% over 20 days), RSI 52
RSI-14: 51.7 · SMA20: $124.62 · SMA50: $117.28
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 30
RSI-14: 29.6 · SMA20: $48.84 · SMA50: $51.79

6-Pillar Scorecard Institutional Category Breakdown (KYMR 4 – 1 CRSP)

Columns: Metric · KYMR · CRSP
1. Valuation Multiples CRSP
Forward P/E N/M 23.4x
Trailing P/E N/M 23.4x
PEG Ratio N/M N/M
EV / Revenue 103.3x N/M
2. Growth & Scale KYMR
Revenue Growth (YoY) +466.4% +1325.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $102M $25M
Market Cap $10.9B $4.1B
3. Profitability & Quality KYMR
Gross Margin N/A N/A
Operating Margin -396.0% -2058.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -27.3% -25.6%
4. Balance Sheet & Cash Flow KYMR
Cash Generation (TTM) -$289M -$378M
Cash Flow Margin N/A N/A
Net Cash / Leverage $297M Net Cash $588M Net Debt (0.47x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KYMR
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 129.6% (23rd %ile) 97.8% (52nd %ile)
Put/Call OI Skew 0.42x (Call-Skewed) 0.65x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KYMR (5) vs CRSP (4)
Institutional Metric KYMR CRSP Criterion Row Edge
Market Capitalization
Scale
$10.9B $4.1B Larger Scale KYMR
Trailing P/E Ratio
Valuation
N/M 23.4x Lower Multiple CRSP
Forward P/E Ratio
Valuation
N/M 23.4x Lower Multiple CRSP
Revenue Growth (YoY)
Growth
+466.4% +1325.1% Higher Growth CRSP
Operating Margin (TTM)
Profitability
-396.0% -2058.6% Higher Margin KYMR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-27.3% -25.6% Higher ROE CRSP
52-Week Range Position
Momentum
78% ($62–$143) 1% ($40–$63) Stronger Trend KYMR
Beta / 30D Volatility
Risk Regime
1.04β · 54% Vol 1.85β · 60% Vol Lower Realized Risk KYMR
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite KYMR
Trailing 12M Revenue (USD)
Operating Scale
$102M $25M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 103.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$289M ($297M Net Cash) -$378M ($588M Net Debt (0.47x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KYMR +36.64 pp
KYMR: +19.1% · CRSP: -17.54%
3M Horizon KYMR +26.14 pp
KYMR: +2.81% · CRSP: -23.33%
6M Horizon KYMR +73.0 pp
KYMR: +56.63% · CRSP: -16.37%
1Y Horizon KYMR +116.66 pp
KYMR: +96.12% · CRSP: -20.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period KYMR Revenue CRSP Revenue KYMR Op. Margin CRSP Op. Margin Margin Leader
FY2018 N/A $0M N/A -5087.8% CRSP
FY2019 $0M $290M -1438.5% 16.1% CRSP
FY2020 $30M $0M -136.1% -49295.5% KYMR
FY2021 $70M $910M -138.0% 40.8% CRSP
FY2022 $50M $0M -344.4% -56190.4% KYMR
FY2023 $80M $370M -210.6% -60.0% CRSP
FY2024 $50M $40M -555.8% -1250.4% KYMR
FY2025 $40M $0M -891.1% -18933.6% KYMR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KYMR CONSOLIDATION
62d in phase · OBV NEUTRAL
Current IV 129.6%
IV Percentile 23rd %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact KYMR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KYMR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.9B market capitalization and -396.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KYMR vs CRSP Key Questions & Quantitative Answers

As of Nov 16, 2026, Kymera Therapeutics, Inc. (KYMR) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). KYMR carries a Unified Composite Score of 47.1/100 (HOLD) at $124.79 (N/M Forward P/E, -396.0% operating margin), whereas CRSP carries 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin). Growth vs. Quality Trade-Off: KYMR earns the overall head-to-head edge with a stronger Unified Composite Score (47.1/100 HOLD vs. CRSP 44.7/100 HOLD) and 1.04β · 54% Vol risk profile, whereas CRSP leads top-line expansion (+1325.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: KYMR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.7); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KYMR leads the Growth & Scale pillar: KYMR posts +466.4% YoY revenue growth and +0.0% YoY earnings growth on $102M TTM revenue (N/A gross margin, -396.0% operating margin), compared with CRSP at +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), KYMR cumulative revenue shifted +33.3% while CRSP shifted -86.2%. In operating R&D and SG&A reinvestment, KYMR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRSP.

CRSP screens cheaper on headline valuation multiples. KYMR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 103.3x EV/Revenue (unreported FCF margin), whereas CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KYMR (-27.3% ROE) versus CRSP (-25.6% ROE) capital efficiency.

In options market volatility and institutional positioning, KYMR carries 129.6% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 54% Vol realized risk). By comparison, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.